(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.60%) $83.35
(-1.16%) $1.619
(0.03%) $2 347.80
(0.95%) $27.51
(0.26%) $924.50
(-0.06%) $0.934
(-0.05%) $11.02
(-0.09%) $0.800
(0.00%) $92.17
-0.38% SEK 103.70
Live Chart Being Loaded With Signals
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases...
Stats | |
---|---|
Volumen de hoy | 204 800 |
Volumen promedio | 201 179 |
Capitalización de mercado | 5.57B |
EPS | SEK0 ( 2024-02-20 ) |
Próxima fecha de ganancias | ( SEK-1.240 ) 2024-05-06 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -11.93 |
ATR14 | SEK0.251 (0.24%) |
Volumen Correlación
Calliditas Therapeutics Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Calliditas Therapeutics Correlación - Moneda/Commodity
Calliditas Therapeutics Finanzas
Annual | 2023 |
Ingresos: | SEK1.21B |
Beneficio Bruto: | SEK1.13B (93.62 %) |
EPS: | SEK-8.69 |
FY | 2023 |
Ingresos: | SEK1.21B |
Beneficio Bruto: | SEK1.13B (93.62 %) |
EPS: | SEK-8.69 |
FY | 2023 |
Ingresos: | SEK0 |
Beneficio Bruto: | SEK0 (0.00 %) |
EPS: | SEK0 |
FY | 2022 |
Ingresos: | SEK802.88M |
Beneficio Bruto: | SEK787.68M (98.11 %) |
EPS: | SEK-7.78 |
Financial Reports:
No articles found.
Calliditas Therapeutics
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico